Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.

Inclusion Criteria: * Male participants aged 18 to 60 years at the time of signing the informed consent form. * Clinical diagnosis of androgenetic alopecia classified as stages 3V, 4, or 5 according to the Norwood-Hamilton scale, based on the investigator's clinical assessment. * No specific treatment for androgenetic alopecia in the last 6 months, or history of specific treatment for androgenetic alopecia for up to 30 days within the last 6 months. * Willingness to comply with all study procedures and assessments, including permanent scalp tattooing and shaving of the target area. * Willingness to maintain hairstyle, hair length, and hair color throughout the study. * Willingness to maintain consistent use of hair products and general hair care routine throughout the study. * Global scalp photograph obtained at Screening Visit validated centrally prior to randomization. Exclusion Criteria: * Presence of other causes of alopecia, such as alopecia areata, scarring alopecia, traction alopecia, nutritional deficiency-related alopecia, monilethrix, trichotillomania, trichodystrophy, or chemotherapy-induced alopecia. * History of telogen effluvium within the last 6 months. * Presence of other dermatological conditions affecting the scalp, such as seborrheic dermatitis, psoriasis, eczema, or fungal infections. * Clinically relevant uncontrolled endocrine disorders that may affect the hair cycle. * Uncontrolled thyroid disease. * History of autoimmune diseases or collagen vascular diseases. * Use of testosterone, its analogues, anabolic steroids, or other systemic androgen therapies within the last 6 months. * History of organ transplantation. * Physical treatments for hair loss within the last 6 months, such as microneedling, laser therapy, or platelet-rich plasma. * History of hair transplantation or use of hairpieces. * Severe uncontrolled systemic arterial hypertension or hypotension. * History of significant cardiovascular disease, including myocardial infarction, unstable angina, or congestive heart failure (NYHA class III or IV). * History or suspicion of pulmonary hypertension associated with mitral stenosis or pheochromocytoma. * History of peripheral edema, lymphedema, ascites, or pericardial effusion. * Resting tachycardia (heart rate ≥100 bpm). * Moderate to severe renal, hepatic, or cardiovascular disease. * History of malignancy within the last 5 years, except for successfully treated non-metastatic basal or squamous cell carcinoma of the skin. * Current use of potent vasodilators or other prohibited medications. * Known allergy or hypersensitivity to minoxidil or any component of the formulation. * Hairstyles that may interfere with study assessments, such as permanent braids or dreadlocks. * Participants with reproductive potential whose partner does not agree to use effective contraception during the study. * Participation in another clinical trial within the last 12 months. * Clinically significant laboratory abnormalities at randomization, including HbA1c ≥8%, estimated glomerular filtration rate \<45 mL/min, elevated liver enzymes (\>2× ULN), abnormal thyroid-stimulating hormone levels, clinically significant ECG abnormalities, hemoglobin \<13 g/dL, or hematocrit \<39%.